Experienced in Immune Thrombocytopenic Purpura (ITP)

Dr. Julie R. Nangia

Hematology Oncology | Hematology | Oncology
2525 A Holly Hall St, 
Houston, TX 
Accepting New Patients
Offers Telehealth
Experienced in Immune Thrombocytopenic Purpura (ITP)
2525 A Holly Hall St, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julie Nangia is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Nangia is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Pancreatic Cancer, and HER-2 Positive Breast Cancer. Dr. Nangia is currently accepting new patients.

Her clinical research consists of co-authoring 29 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baylor St Lukes Medical Center
Harris Health
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

BAYLOR COLLEGE OF MEDICINE
2525 A Holly Hall St, Houston, TX 77054
Other Locations
BAYLOR COLLEGE OF MEDICINE
6770 Bertner Ave, Suite C 350, Houston, TX 77030
BAYLOR COLLEGE OF MEDICINE
7200 Cambridge St, Houston, TX 77030
BAYLOR COLLEGE OF MEDICINE
1502 Taub Loop, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
Intervention Type: Drug
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: ZN-c5, Palbociclib
Study Phase: Phase 1/Phase 2
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors
A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors
Enrollment Status: Terminated
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer
A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 09, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

29 Total Publications

Multilevel barriers and supportive care preferences of metastatic breast cancer patients and their caregivers: a mixed-methods analysis.
Multilevel barriers and supportive care preferences of metastatic breast cancer patients and their caregivers: a mixed-methods analysis.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: August 05, 2024
Similar Doctors
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Lawrence Rice
Hematology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Lawrence Rice
Hematology

Tmh Physician Associates PLLC

7575 San Felipe St, Suite 155, 
Houston, TX 
 (8.2 miles away)
713-266-9955
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lawrence Rice is a Hematologist in Houston, Texas. Dr. Rice is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Thrombocytopenia, Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Rice is currently accepting new patients.

Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Shahab A. Khan
Hematology Oncology | Hematology | Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Shahab A. Khan
Hematology Oncology | Hematology | Oncology

North Houston Medicine Tumor And Blood Clinic, P.A.

1631 N Loop W, Suite 100, 
Houston, TX 
 (9.1 miles away)
713-862-5695
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shahab Khan is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Khan is rated as an Advanced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Familial Colorectal Cancer, Pleuropulmonary Blastoma, Adult Immune Thrombocytopenia, and Immune Thrombocytopenic Purpura (ITP). Dr. Khan is currently accepting new patients in some locations.

Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Eric P. Kleinbaum
Hematology Oncology | Hematology | Oncology
Advanced in Immune Thrombocytopenic Purpura (ITP)
Dr. Eric P. Kleinbaum
Hematology Oncology | Hematology | Oncology

American Oncology Partners PA

135 Vision Park Blvd, 
Shenandoah, TX 
 (35.1 miles away)
936-235-7092
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eric Kleinbaum is a Hematologist Oncology specialist and a Hematologist in Shenandoah, Texas. Dr. Kleinbaum is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Childhood Iron Deficiency Anemia, and Pleuropulmonary Blastoma. Dr. Kleinbaum is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nangia's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile